SunAct & CytoMed join hands for Ph 2 clinical trials of innovative cancer therapy in India

India's SunAct Cancer Institute has announced the start of Phase 2 clinical trials on a groundbreaking treatment called gd (Gamma Delta) T-cell therapy. This trial, conducted in collaboration with CytoMed, Singapore, aims to bring hope to patients with difficult-to-treat cancers such as brain cancer, breast cancer, lung cancer, cervical cancer, colon cancer, renal cancer, liver cancer , lymph node cancer  and several others.

This is a cutting-edge cancer treatment that uses special immune cells called Gamma Delta T-Cells. These cells naturally fight cancer while protecting the healthy tissue. What makes this treatment unique is that it uses ready-made cells from donors, making it faster, easier, and less expensive compared to traditional therapies.

This trial marks a major collaboration between SunAct Cancer Institute in India and CytoMed, a leader in cancer treatments from Singapore. Together, they aim to offer world-class cancer care to patients in India. The trial will begin in early 2025, and patients will soon be able to enroll.